Anne-Laure Gagez is an expert in Oncology at University Hospital of Montpellier (France). Anne-Laure Gagez has authored 22 publications, the most recent in 2023. SLR score: 56 (community average: 125). How the SLR is computed.

LeadR Profile

Anne-Laure Gagez University Hospital of Montpellier France
56 ScienceLeadR Reputation 56
Network Map

Oncology

Subspecialties:

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2011 - 2023

Source: PubMed

Centre Oscar Lambret

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 22

Citations

Citations: 532 1st author: 6 Last author: 0 Unique author: 0


Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Pediatric Palliative Care for a French Hospital-At-Home Facility: A Case Report.
PMID 37676183 — palliative care, pediatrics, pediatric nursing
J Pediatr Health Care20230
miRNA profile at diagnosis predicts treatment outcome in patients with B-chronic lymphocytic leukemia: A FILO study.
PMID 36325355 — diagnosis, immune system diseases, rna, biomarkers, cells, therapeutics, leukemia, lymphocytic, chronic, b-cell, treatment outcome, genes, aftercare, blood, leukemia, lymphoid, micrornas
Front Immunol20225
Angiogenic factors could help us to define patients obtaining complete response with undetectable minimal residual disease in untreated CLL patients treated by FCR: results from the CLL2010FMP, a FILO study.
PMID 34806520 — neoplasm, residual, lymphoma, diagnosis, disease-free survival, leukemia, progression-free survival
Leuk Lymphoma20210
A Retrospective Comparison of DLI and gDLI for Post-Transplant Treatment.
PMID 32664688 — stem cells, therapeutics, microscopy, electron, scanning transmission, disease-free survival, transplants, lymphoma, non-hodgkin, graft vs host disease, progression-free survival
J Clin Med202010
C-Reactive Protein Level: A Key Predictive Marker of Cachexia in Lymphoma and Myeloma Patients.
PMID 32300444 — lymphoma, diagnosis, risk factors, c-reactive protein, cachexia
J Hematol201918

LeadR Networks

Main global connection map